GSK unit sues AnaptysBio in row over Jemperli rights

GSK’s US unit Tesaro has sued AnaptysBio in the Delaware Court of Chancery, asking the court to confirm that alleged breaches of their 2014 licence let Tesaro terminate the contract, retain a perpetual licence to Jemperli (dostarlimab) and cut in half the royalty and milestone payments owed to AnaptysBio. The filing follows reciprocal accusations from AnaptysBio that Tesaro failed to meet contractual obligations and sought to revoke the licence, allegations GSK and Tesaro call “entirely without merit.” Because Jemperli is a fast‑growing immunotherapy for endometrial cancer approved in more than 35 countries with expanding sales and ongoing trials in additional indications, the litigation creates a material commercial and revenue risk that could alter future royalty streams and partner economics for both companies.

Analysis

GSK’s US subsidiary Tesaro has initiated litigation against AnaptysBio in the Delaware Court of Chancery, asking the court to confirm that alleged breaches of their 2014 licence allow Tesaro to terminate the contract, retain a perpetual licence to Jemperli (dostarlimab) and cut royalty and milestone payments by half. AnaptysBio has countered with allegations that Tesaro failed to meet contractual obligations and seeks to revoke the licence; GSK and Tesaro characterize those counterclaims as "entirely without merit."

Jemperli is described as a fast‑growing immunotherapy for endometrial cancer with approvals in more than 35 countries, ongoing global trials in rectal, colon and head‑and‑neck cancers, and accelerating sales after wider approvals. The asset-level strength increases the commercial stakes of the dispute because licence economics (upfronts, milestones, royalties) directly affect future revenue allocation between the parties.

The market signal is mixed: a market impact score of 0.34 with per‑ticker sentiment of +0.6 for GSK and -0.6 for ANAB highlights investor uncertainty. Outcome risk is binary and material to partner economics and cash flow; timeline and court interpretation of the 2014 agreement will drive near‑term volatility and potential revisions to revenue recognition and cash‑flow forecasts.

Key Decisions for Investors

• Monitor Delaware Court filings and company disclosures closely and re‑assess position sizing as material motions or a ruling emerge, since a Tesaro win could reduce royalty outflows and boost GSK cash flow
• AnaptysBio holders should consider hedging or reducing exposure ahead of legal clarity given negative sentiment and the risk of reduced future royalties or licence termination
• Track Jemperli commercial metrics (sales trends post‑wider approvals) and readouts from rectal, colon and head‑and‑neck trials as these will materially affect negotiating leverage and long‑term revenue potential for both parties